Long-term safety study of litifilimab for skin lupus
Part of Skin clinical trials.
This study is a long-term follow-up for people who already completed a 52-week study of the study drug litifilimab for active skin lupus. It will check the safety of continued treatment and see if it keeps helping symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed the full 52-week parent study (all treatments and study visits).
- You should not have stopped treatment or dropped out early from the parent study.
- You must not have developed any new medical conditions that make this study unsafe for you.
- You must be able to understand the study and give your permission (consent) to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This extension study tests the long-term safety of ianalumab for people with systemic lupus erythematosus. If you completed a prior SIRIUS-SLE study and your doctor thinks you'd benefit, you may continue treatment for up to 60 more weeks.
This study is for people who have completed an earlier clinical trial for pulmonary fibrosis. It checks the long-term safety and tolerability of the study drug.
This study follows people with systemic lupus erythematosus (SLE) who already took part in an earlier, 1-year placebo-controlled trial. It looks at the long-term safety of litifilimab and whether it helps improve lupus symptoms over time.
This study tests a new investigational drug called SCTB35 for people with active systemic lupus erythematosus (SLE or lupus). It aims to see if the drug is safe and effective in controlling lupus activity when added to your current stable lupus medications.
This study tests a new drug called LBL-047 in healthy people and in people with mild to moderate lupus. It helps check if the drug is safe and how the body processes it. Participating may help find better treatments for lupus.
This study is a long-term follow-up of a drug called enpatoran. People who completed the earlier Elowen-1 or Elowen-2 studies can continue taking the drug to see if it keeps helping their lupus skin symptoms safely over time.
Hear when a new Subacute Cutaneous Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.